{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:15:56Z","timestamp":1790615756431,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105344","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:07:08Z","timestamp":1776899228000},"page":"105344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-3926","authenticated-orcid":false,"given":"K\u00fcbra","family":"Canaslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Ba\u015fb\u0131nar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lhan","family":"\u00d6ztop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.critrevonc.2026.105344_bib1","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","article-title":"Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C Inhibitor in KRAS G12C-mutant non-small cell lung cancer","volume":"26","author":"Adachi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105344_bib2","unstructured":"Aisner D.L., Ettinger D.S., Wood D.E., et al. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 6.2022. National Comprehensive Cancer Network; 2022. Accessed 16th December 2026."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105344_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtho.2023.01.091","article-title":"Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC","volume":"18","author":"Alessi","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105344_bib4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of co-occurring genomic alterations on outcomes in patients with kras-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105344_bib5","doi-asserted-by":"crossref","unstructured":"Arbour K., Tawee T., Yaeger R., Parikh A., Oberstein P., Papadopoulos K., et al. nd Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors. Cancer Research. 85. CT019-CT019. 10.1158\/1538-7445.AM2025-CT019.","DOI":"10.1158\/1538-7445.AM2025-CT019"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105344_bib6","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.3390\/cancers17142388","article-title":"Co-occurring genomic alterations in nsclc: making order into a crowded list","volume":"17","author":"Attili","year":"2025","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105344_bib7","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"New Engl. J. Med."},{"issue":"10503","key":"10.1016\/j.critrevonc.2026.105344_bib8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105344_bib9","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.ccell.2025.05.006","article-title":"Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy","volume":"43","author":"Benton","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105344_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.787585","article-title":"Resistance to KRASG12C inhibitors in non-small cell lung cancer","volume":"11","author":"Blaquier","year":"2021","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105344_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105344_bib12","article-title":"Efficacy and safety of olomorasib in combination with pembrolizumab in treatment of patients with KRAS G12C-mutant advanced NSCLC","volume":"20","author":"Burns","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"7781","key":"10.1016\/j.critrevonc.2026.105344_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105344_bib14","doi-asserted-by":"crossref","first-page":"S1062","DOI":"10.1016\/j.annonc.2025.08.2470","article-title":"1846MO Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases","volume":"36","author":"Cassier","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105344_bib15","doi-asserted-by":"crossref","unstructured":"Cassier P., Dooms C., Gazzah A., Felip E., Steeghs N., Rohrberg K. et al nd, KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C -mutated solid tumors including non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 41. 9007-9007. 10.1200\/JCO.2023.41.16_suppl.9007.","DOI":"10.1200\/JCO.2023.41.16_suppl.9007"},{"key":"10.1016\/j.critrevonc.2026.105344_bib16","doi-asserted-by":"crossref","unstructured":"Clarke J., Yaeger R., Felip E., Rodriguez J.C. nd, Garrido Pilar, Zugazagoitia J. et al. 1991P Overall survival (OS) with sotorasib plus carboplatin and pemetrexed in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) from the global phase Ib CodeBreaK 101 study. Annals of Oncology. 36. S1133-S1134. 10.1016\/j.annonc.2025.08.2615.","DOI":"10.1016\/j.annonc.2025.08.2615"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105344_bib17","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10378","key":"10.1016\/j.critrevonc.2026.105344_bib18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105344_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.796832","article-title":"Targeting KRAS mutant in non-Small cell lung cancer: novel insights into therapeutic strategies","volume":"12","author":"D\u00e9sage","year":"2022","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105344_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1158\/0008-5472.CAN-17-2084","article-title":"KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment","volume":"78","author":"Dias Carvalho","year":"2018","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105344_bib21","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105344_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/cancers13010151","article-title":"Mechanisms of resistance to KRASG12C inhibitors","volume":"13","author":"Dunnett-Kane","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105344_bib23","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3390\/cancers14092063","article-title":"KRAS Mutations impact clinical outcome in metastatic non-small cell lung cancer","volume":"14","author":"Eklund","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105344_bib24","doi-asserted-by":"crossref","unstructured":"Falchook G., Li B.T., Marrone K.A., Bestvina C.M., Langer C.J., Krauss J., et al. nd OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors. Journal of Thoracic Oncology. 17. S8. 10.1016\/j.jtho.2022.07.022.","DOI":"10.1016\/j.jtho.2022.07.022"},{"key":"10.1016\/j.critrevonc.2026.105344_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2018.07.013","article-title":"KRAS-Mutant non-small cell lung cancer: From biology to therapy","volume":"124","author":"Ferrer","year":"2018","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105344_bib26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/ijms22020612","article-title":"Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer","volume":"22","author":"Fois","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105344_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2026.108930","article-title":"KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence","volume":"213","author":"Gang","year":"2026","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105344_bib28","doi-asserted-by":"crossref","unstructured":"Garassino M.C., Theelen WSME, Jotte R., Laskin J., de Marinis F., Aguado C. et al. nd, LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-na\u00efve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Annals of Oncology, Volume 34, S1309 - S1310. 10.1016\/j.annonc.2023.10.066.","DOI":"10.1016\/j.annonc.2023.10.066"},{"key":"10.1016\/j.critrevonc.2026.105344_bib29","doi-asserted-by":"crossref","unstructured":"Gimple R.C., Wang X. RAS: Striking at the Core of the Oncogenic Circuitry. Front Oncol. 2019 Sep 24;9:965. https:\/\/doi.org\/10.3389\/fonc.2019.00965. PMID: 31681559; PMCID: PMC6798062.","DOI":"10.3389\/fonc.2019.00965"},{"key":"10.1016\/j.critrevonc.2026.105344_bib30","doi-asserted-by":"crossref","first-page":"8635","DOI":"10.1200\/JCO.2024.42.16_suppl.8635","article-title":"KRAS mutation subtypes responded differently to combination immunotherapy via disturbing myeloid-derived suppressor cells in non-small cell lung cancer","volume":"42","author":"Gong","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105344_bib31","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1016\/j.jtho.2025.09.823","article-title":"P3.03.25 A combination therapy strategy that targets both KRAS-G12C and GSK3 for non-small cell lung cancer","volume":"20","author":"Gong","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105344_bib32","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez D., Zhou M., Codony-Servat Jordi, Wang Y., Oliveira N., Zhang J., et al. nd EP.02.10 Fumarate and Ass1 in KRAS-Mutant NSCLC: The Influence of Cetuximab in Combination With KRAS G12C Inhibitors (Sotorasib and Fulzerasib). Journal of Thoracic Oncology. 20. S645-S646. \u300810.1016\/j.jtho.2025.09.1225\u3009.","DOI":"10.1016\/j.jtho.2025.09.1225"},{"issue":"7417","key":"10.1016\/j.critrevonc.2026.105344_bib33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Cancer genome atlas research network. comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"Hammerman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105344_bib34","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1016\/j.jtho.2025.09.500","article-title":"P2.02.29 CXCR2 Inhibitor Plus KRAS G12C inhibitor remodels immunosuppressive tumor microenvironment in KRAS G12C-Mutant NSCLC?","volume":"20","author":"He","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105344_bib35","doi-asserted-by":"crossref","unstructured":"Heist R., Koyama T., Murciano-Goroff Y., Hollebecque A., Cassier P., Han J.Y., et al. nd Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors. Journal of Clinical Oncology. 42. 3007-3007. 10.1200\/JCO.2024.42.16_suppl.3007.","DOI":"10.1200\/JCO.2024.42.16_suppl.3007"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105344_bib36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105344_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105344_bib38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105344_bib39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fonc.2017.00193","article-title":"Lung cancer: understanding its molecular pathology and the 2015 who classification","volume":"7","author":"Inamura","year":"2017","journal-title":"Front Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105344_bib40","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.3390\/cancers13246332","article-title":"Targeting KRAS in NSCLC: old failures and new options for \"non-G12c\" patients","volume":"13","author":"Jacobs","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105344_bib41","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent g12c-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105344_bib42","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105344_bib43","doi-asserted-by":"crossref","first-page":"PR014","DOI":"10.1158\/1535-7163.TARG-23-PR014","article-title":"Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment","volume":"22","author":"J\u00e4nne","year":"2023","journal-title":"Mol. Cancer Ther. 1"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105344_bib44","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS mutation subtypes in non-small cell lung cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105344_bib45","doi-asserted-by":"crossref","first-page":"S686","DOI":"10.1016\/j.jtho.2025.09.1311","article-title":"EP.06.17 immunological and genetic profile and efficacy of immunotherapy in nsclc patients with mutations in KRAS and STK11 Genes","volume":"20","author":"Krawczyk","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105344_bib46","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"issue":"6168","key":"10.1016\/j.critrevonc.2026.105344_bib47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105344_bib48","doi-asserted-by":"crossref","first-page":"23874","DOI":"10.18632\/oncotarget.8074","article-title":"Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105344_bib49","doi-asserted-by":"crossref","unstructured":"Lee C.K., Zhou D.D.-X., Brown C., Bray V., Ding P., Itchins M., et al. nd OA08.04 Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced KRAS G12C NSCLC. Journal of Thoracic Oncology. 20. S27-S28. 10.1016\/j.jtho.2025.09.057.","DOI":"10.1016\/j.jtho.2025.09.057"},{"key":"10.1016\/j.critrevonc.2026.105344_bib50","first-page":"S59","article-title":"OA03.06 CodeBreaK 100\/101: first report of safety\/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC","volume":"20","author":"Li","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105344_bib51","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","article-title":"Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105344_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0307580","article-title":"Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma","volume":"19","author":"Liang","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2026.105344_bib53","doi-asserted-by":"crossref","first-page":"S1134","DOI":"10.1016\/j.annonc.2025.08.2616","article-title":"1992P Targeting KRAS codon 13 mutations using combinations with RMC-8839, a novel RAS(ON) G13C-selective, tri-complex inhibitor, in non-small cell lung cancer","volume":"36","author":"Lindsay","year":"2025","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105344_bib54","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/s41588-025-02297-w","article-title":"Tracing the evolution of single-cell 3D genomes in Kras-driven cancers","volume":"57","author":"Liu","year":"2025","journal-title":"Nat. Genet"},{"key":"10.1016\/j.critrevonc.2026.105344_bib55","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.jtho.2025.09.110","article-title":"MA02.07 Efficacy and Safety of GFH375 in Advanced Non-small Cell Lung Cancer Patients with KRAS G12D Mutation","volume":"20","author":"Lu","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105344_bib56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2021.01.015","article-title":"RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients","volume":"146","author":"Malapelle","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"41","key":"10.1016\/j.critrevonc.2026.105344_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade3816","article-title":"Acquired resistance to KRAS G12C small-molecule inhibitors via genetic\/nongenetic mechanisms in lung cancer","volume":"9","author":"Mohanty","year":"2023","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105344_bib58","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105344_bib59","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/j.molcel.2024.06.027","article-title":"Functional and structural insights into RAS effector proteins","volume":"84","author":"Mozzarelli","year":"2024","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2026.105344_bib60","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-024-02036-3","article-title":"New insights into protein\u2013protein interaction modulators in drug discovery and therapeutic advance","volume":"9","author":"Nada","year":"2024","journal-title":"Sig Transduct. Target Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105344_bib61","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/JTO.0000000000000305","article-title":"KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma","volume":"9","author":"Nadal","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105344_bib62","doi-asserted-by":"crossref","unstructured":"Negrao M.V., Uyeki J.V., Cicin I., Chen Y., Shim B.Y., Yamaguchi M. et al. nd OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01. Journal of Thoracic Oncology. 20. S26-S27. 10.1016\/j.jtho.2025.09.055.","DOI":"10.1016\/j.jtho.2025.09.055"},{"key":"10.1016\/j.critrevonc.2026.105344_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1239000","article-title":"Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C","volume":"13","author":"Notario","year":"2023","journal-title":"Front Oncol."},{"issue":"7477","key":"10.1016\/j.critrevonc.2026.105344_bib64","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105344_bib65","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-Human Phase I\/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105344_bib66","doi-asserted-by":"crossref","unstructured":"Pinto L., Rocha P., Clave S., Navarro-Gorro N., Sanchez I., Giner M. et al. nd 193P Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC. Journal of Thoracic Oncology. 18. S145-S146. 10.1016\/S1556-0864(23)00446-X.","DOI":"10.1016\/S1556-0864(23)00446-X"},{"key":"10.1016\/j.critrevonc.2026.105344_bib67","doi-asserted-by":"crossref","unstructured":"Punekar S., Hong D., Luo, J., Ou S.-H.I., Johnson M.L., Spira A. et al. nd, 6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 20. S10-S11. 10.1016\/S1556-0864(25)00201-1.","DOI":"10.1016\/S1556-0864(25)00201-1"},{"issue":"12_ement","key":"10.1016\/j.critrevonc.2026.105344_bib68","doi-asserted-by":"crossref","first-page":"ND11","DOI":"10.1158\/1538-7445.AM2022-ND11","article-title":"Abstract ND11: Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers","volume":"82","author":"Purkey","year":"2022","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105344_bib69","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/cancers14051321","article-title":"Direct targeting KRAS mutation in non-small cell lung cancer: focus on resistance","volume":"14","author":"Reita","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105344_bib70","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-02825","article-title":"Therapy for stage IV non\u2013small cell lung cancer without driver alterations: ASCO living guideline, 2026.3.0","volume":"44","author":"Reuss","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105344_bib71","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(Ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma Is Affected by KRAS Mutation Status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105344_bib72","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12943-018-0789-x","article-title":"KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target","volume":"17","author":"Rom\u00e1n","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105344_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00040","article-title":"Single-agent divarasib in patients with KRAS G12C\u2013positive non\u2013small cell lung cancer: long-term follow-up of a phase i study","author":"Sacher","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105344_bib74","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105344_bib75","doi-asserted-by":"crossref","first-page":"346","DOI":"10.21037\/tlcr-22-639","article-title":"Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review","volume":"12","author":"Santarpia","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105344_bib76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The rise of molecular glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105344_bib77","first-page":"P1.17","article-title":"49 Real-World Outcomes with IO and Chemo-IO demonstrate unmet need for 1L KRAS G12C-mutant advanced NSCLC in the US","author":"Sheffield","year":"2025","journal-title":"J. Thorac. Oncol. 20 S234"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105344_bib78","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.2016.71.2893","article-title":"Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy","volume":"35","author":"Shepherd","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105344_bib79","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non\u2013small cell lung cancer resistant to immune checkpoint inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105344_bib80","doi-asserted-by":"crossref","unstructured":"Shono K., Watanabe S., Masuda T., Suzuki R., Wakabayashi T., Sekiya T., et al. nd Abstract 5263: The impact of MRTX1133 on anti-tumor immunity in lung cancer with KRASG12D mutation. Cancer Research. 84. 5263-5263. 10.1158\/1538-7445.AM2024-5263.","DOI":"10.1158\/1538-7445.AM2024-5263"},{"key":"10.1016\/j.critrevonc.2026.105344_bib81","article-title":"Cancer statistics, 2026","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105344_bib82","doi-asserted-by":"crossref","unstructured":"Simonelli M., Rojas C.I., Dziadziuszko R., Park, J.O., Xue, J., Felip E., et al., nd 926MO MK-1084 monotherapy in participants (Pts) with KRAS G12C\u2013mutated advanced solid tumors: Activity and safety in the phase I KANDLELIT-001 study. Annals of Oncology. 36. S606-S607. \u300810.1016\/j.annonc.2025.08.1495\u3009.","DOI":"10.1016\/j.annonc.2025.08.1495"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105344_bib83","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/1078-0432.CCR-20-1985","article-title":"NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes","volume":"27","author":"Singh","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105344_bib84","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41698-024-00644-4","article-title":"Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC","volume":"8","author":"Sisoudiya","year":"2024","journal-title":"NPJ Precis Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105344_bib85","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"New Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105344_bib86","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105344_bib87","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105344_bib88","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105344_bib89","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105344_bib90","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-021-01422-7","article-title":"Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges","volume":"20","author":"Tang","year":"2021","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105344_bib91","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41417-024-00778-4","article-title":"Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential","volume":"31","author":"Tang","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105344_bib92","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","article-title":"Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer","volume":"42","author":"Tong","year":"2024","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105344_bib93","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105344_bib94","doi-asserted-by":"crossref","first-page":"S652","DOI":"10.1016\/j.jtho.2025.09.1241","article-title":"EP.03.14 Single-Cell Transcriptome Analysis Revealed an Activated Tumor Immune Microenvironment in KRAS Mutant NSCLC","volume":"20","author":"Wang","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105344_bib95","article-title":"Additional impact of genetic ancestry over race\/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer","volume":"5","author":"Wang","year":"2024","journal-title":"HGG Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105344_bib96","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12943-025-02364-0","article-title":"Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs","volume":"24","author":"Wang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105344_bib97","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/2159-8290.CD-22-0158","article-title":"Discovery, preclinical characterization, and early clinical activity of JDQ443, a structurally novel, potent, and selective covalent oral inhibitor of KRASG12C","volume":"12","author":"Weiss","year":"2022","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105344_bib98","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamaoncol.2016.0405","article-title":"Salgia R. prognostic and predictive value in KRAS in non-small-cell lung cancer: a review","volume":"2","author":"Wood","year":"2016","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105344_bib99","article-title":"Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan","volume":"2","author":"Wu","year":"2020","journal-title":"JTO Clin. Res Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105344_bib100","doi-asserted-by":"crossref","first-page":"S1056","DOI":"10.1016\/j.annonc.2025.08.2613","article-title":"1989P Efficacy and safety of fulzerasib in patients (pts) with KRAS G12C-mutant non-small cell lung cancer (NSCLC): updated results from phase I\/II studies","volume":"36","author":"Wu","year":"2025","journal-title":"Ann. Oncol."},{"issue":"7790","key":"10.1016\/j.critrevonc.2026.105344_bib101","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105344_bib102","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2021.02.002","article-title":"KRAS G12C-mutant non-small cell lung cancer: biology, developmental therapeutics, and molecular testing","volume":"23","author":"Veluswamy","year":"2021","journal-title":"J. Mol. Diagn."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105344_bib103","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12935-024-03498-9","article-title":"The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis","volume":"24","author":"Zhao","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.critrevonc.2026.105344_bib104","doi-asserted-by":"crossref","unstructured":"Zhou M., Gonz\u00e1lez D., Nieto J., Valencia K., Wang Y., Zhang J., et al. nd 3030eP Fulzerasib plus cetuximab prevents resistance in KRAS G12C NSCLC suppressing NRF2, AURKA and PRMT1. Annals of Oncology. 36. S1574. \u300810.1016\/j.annonc.2025.08.3645\u3009.","DOI":"10.1016\/j.annonc.2025.08.3645"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:03:44Z","timestamp":1780038224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":104,"alternative-id":["S1040842826002313"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105344","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105344","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105344"}}